Abstracts tagged "Infection"

Abstract Number: 2079 • 2016 ACR/ARHP Annual Meeting
Incidence and Risk of Pneumocystis Jirovecii Pneumonia Following Rituximab Treatment in Granulomatosis with Polyangiitis in the United States: An Analysis from a National Database
Sirada Panupattanapong¹, Anthony R. French², Andrew J. White², Margaret A. Olsen³, Maya Rendulic⁴ and Mary E. Hartman⁵, ¹Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ²Division of Pediatric Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ³Division of Infectious Disease, Washington University School of Medicine, St. Louis, MO, ⁴Center for Administrative Data Research, Washington University School of Medicine, St. Louis, MO, ⁵Division of Pediatric Critical Care Medicine, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO
Background/Purpose: Pneumocystis Jirovecii pneumonia (PJP) is a life-threatening complication in granulomatosis with polyangiitis (GPA). Guidelines from EULAR for ANCA-associated vasculitis (AAV) recommend institution of PJP…
Abstract Number: 689 • 2016 ACR/ARHP Annual Meeting
Relationship Between Infliximab Serum Concentrations and Risk of Infections in Patients Treated for Spondyloarthritis
Theodora Bejan-Angoulvant¹, David Ternant², Fadela Daoued³, Frédéric Medina³, Louis Bernard⁴, Saloua Mammou³, Gilles Paintaud² and Denis Mulleman⁵, ¹Service de Pharmacologie Clinique, CHRU de Tours, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, ²Laboratoire de Pharmacologie-Toxicologie, Université François-Rabelais de Tours, CNRS 7292, CHRU de Tours, Tours, France, ³Service de Rhumatologie, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, ⁴Service des Maladies Infectieuses, Université François-Rabelais de Tours, CHRU de Tours, Tours, France, ⁵Service de Rhumatologie, Rheumatology department, François-Rabelais University, CNRS 7292, CHRU de Tours, Tours, France
Background/Purpose: Tumour necrosis factor alpha inhibitors are effective in reducing inflammation in rheumatic diseases while increasing the risk of infections. We aimed to study the…
Abstract Number: 2310 • 2016 ACR/ARHP Annual Meeting
The Predictive Risk Factors for Complication of Infection during the Treatment for Inflammatory Myopathies Complicated with Interstitial Lung Disease
Yumiko SUGIYAMA^1,2, Maasa Tamura^1,2,3, Ryusuke Yoshimi^1,2, Naoki Hamada^1,2, Hideto Nagai^1,2, Yuko Tatekabe^1,2, Naomi Tsuchida^2,4, Yutaro Soejima^1,2, Yosuke Kunishita^2,4, Daiga Kishimoto^1,2, Hiroto Nakano^1,2, Reikou Kamiyama^1,2, Kaoru Minegishi^2,5, Yukiko Asami^1,2, Yohei Kirino^2,4, Shigeru Ohno^2,5 and Hideaki Nakajima¹, ¹Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Y-CURD Study Group, Yokohama, Japan, ³Nagaoka Red Cross Hospital, Nagaoka, Japan, ⁴Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan, ⁵Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Interstitial lung disease (ILD) is one of the predominant causes of death in polymyositis/dermatomyositis (PM/DM). We have already reported that low PaCO2 and interstitial…
Abstract Number: 1521 • 2015 ACR/ARHP Annual Meeting
Screening for Urinary Tract Infection in Rheumatoid Arthritis Patients Treated with TNF-Inhibitors in the Daily Clinic
Renata Baronaite Hansen¹, Anne Brun Hesselvig², Rolf Magnus Arpi², Eva Kristin Jonassen¹, Gunhild Bukh¹ and Ole Rintek Madsen¹, ¹Department of Rheumatology/C, Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup, Denmark, ²Department of Clinical Microbiology, Department of Clinical Microbiology, Copenhagen University Hospital Herlev, Herlev, Denmark
Background/Purpose: Patients with rheumatoid arthritis (RA) treated with biologic agents are at increased risk of infection. Therefore, screening for urinary tract infection (UTI) with urine…
Abstract Number: 1692 • 2015 ACR/ARHP Annual Meeting
Serious Infections in Psoriasis Patients with Psoriatic Arthritis in the Psoriasis Longitudinal Assessment and Registry Study
Christopher T. Ritchlin¹, Alice B. Gottlieb², Alan Menter³, Philip J. Mease⁴, Sunil Kalia⁵, Francisco Kerdel⁶, Shelly Kafka⁷, G James Morgan⁷, Wayne Langholff⁸, Steve Fakharzadeh⁷ and Kavitha Goyal⁷, ¹Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ²Tufts Medical Center and Tufts University School of Medicine, Boston, MA, ³Baylor University Medical Center, Dallsa, TX, ⁴Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶University of Miami, Miami, FL, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, ⁸Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: To describe the rates of serious infections in psoriasis patients with psoriatic arthritis(PsA) from PSOLAR. Methods: PSOLAR is an international, disease-based, observational study in…
Abstract Number: 2032 • 2015 ACR/ARHP Annual Meeting
Chaperonin Protein 14-3-3eta, Cyclic Citrullinated Peptide Antibody, and Rheumatoid Factor in the Differential Diagnosis of Chikungunya Arthritis Versus Rheumatoid Arthritis
Olga S. Zhukov¹, Rania W. Abolhosn¹, Jonnielyn G. Rivera¹, Mary Lape Nixon², Robert J. Lagier³, Harry E. Prince⁴, Hollis J. Batterman⁴ and Stanley J. Naides¹, ¹Immunology, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA, ²Lab Sciences, Quest Diagnostics Focus Clinical Reference Laboratory, San Juan Capistrano, CA, ³Research Support, Alameda, Quest Diagnostics Alameda, Alameda, CA, ⁴Lab Services, Quest Diagnostics Focus Clinical Reference Laboratory, San Juan Capistrano, CA
Background/Purpose: Chikungunya fever virus (CHIK) is emerging in the western hemisphere as a mosquito-borne, acute onset arthritis. The majority of cases progress to persistent moderate…
Abstract Number: 2034 • 2015 ACR/ARHP Annual Meeting
Nontuberculous Mycobacterial Diseases Do Not Cause Positive Autoantibody Testing, Results from a Tertiary Pulmonary Care Center
Barbara Goldstein¹, Jeffery J. Swigris², Shannon Kasperbauer¹, Pearlanne Zelarney¹ and JoAnn Zell¹, ¹Medicine, National Jewish Health, Denver, CO, ²National Jewish Health, Denver, CO
Background/Purpose: National Jewish Health (NJH) is a tertiary referral center for pulmonary and immunologic disease. The infectious disease division at NJH specializes in the care…
Abstract Number: 2050 • 2015 ACR/ARHP Annual Meeting
Herpes Zoster during the Tofacitinib Clinical Development Program for RA: Characterization of Herpes Zoster Incidence and Evaluation of Whether Herpes Zoster Predicts Subsequent Serious Infections or Malignancy
Kevin L. Winthrop¹, Yoshiya Tanaka², Kunihiro Yamaoka³, Jeffrey R. Curtis⁴, Chudy Nduaka⁵, Haiyun Fan⁵, Pinaki Biswas⁶, Tomohiro Hirose⁷, Sriram Krishnaswami⁸, Hernan Valdez⁶, Shigeyuki Toyoizumi⁷, Koshika Soma⁸ and Connie Chen⁶, ¹Oregon Health & Science University, Portland, OR, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Keio University, Tokyo, Japan, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Japan Inc, Tokyo, Japan, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The risk of herpes zoster (HZ) was elevated within the tofacitinib clinical…
Abstract Number: 2251 • 2015 ACR/ARHP Annual Meeting
Current Tobacco Use and the Rates of Postoperative Complications after Total Knee Arthroplasty
Jasvinder A. Singh, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To our knowledge, well-designed studies that have examined the risk of post-arthroplasty implant-related complications after TKA with tobacco use are lacking. Our objective was…
Abstract Number: 2799 • 2015 ACR/ARHP Annual Meeting
Varicella Zoster Reactivation in Patients with Primary Sjögren’s Syndrome and SLE
Eliza F. Chakarvarty¹, Jacy Odell², Astrid Rasmussen³, Kathy L. Sivils², Joel M. Guthridge² and Judith A. James⁴, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, CA, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Increasing data has suggested that individuals with systemic lupus (SLE) are at increased risk of herpes zoster (HZ) reactivation compared to healthy controls and…
Abstract Number: 49 • 2015 ACR/ARHP Annual Meeting
Dose Relationship Between Oral Glucocorticoids and TNF Inhibitors and the Risk of Hospitalized Infectious Events Among Patients with Rheumatoid Arthritis
Neil Accortt¹, Jennifer Schenfeld² and Mona Trivedi³, ¹Amgen, Inc., Thousand Oaks, CA, ²Docs Global, Inc, North Wales, PA, ³Rheumatology, Amgen, Thousand Oaks, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at an increased risk for serious hospitalized infectious events (HIEs). Research suggests that tumor necrosis factor alpha inhibitors…
Abstract Number: 2817 • 2015 ACR/ARHP Annual Meeting
The Microbiome of Reactive Arthritis in a Guatemalan Cohort
Alexis Ogdie-Beatty¹, Carles Ubeda², Helga Raquel Garcia Ferrer³, Joan Von Feldt⁴, A Garcia Kutzbach⁵ and Jose U. Scher⁶, ¹Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Institute for Research in Public Health, Valencia, Spain, ³Society for Worldwide Med Exchange, North Bay Village, FL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Internal Medicine, Rheumatology Unit (AGAR), Francisco Marroquin University, School of Medicine, Guatemala City, Guatemala, ⁶Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Reactive arthritis (ReA) is an inflammatory arthritis that typically follows infection. Several agents microbial agents have been implicated, particularly Shigella, Salmonella, Campylobacter in the…
Abstract Number: 566 • 2015 ACR/ARHP Annual Meeting
Genome-Wide Trans-Ancestry Meta-Analysis of Herpes Zoster in RA and Pso Patients Treated with Tofacitinib
Nan Bing¹, HuanYu Zhou¹, BaoHong Zhang¹, John D Bradley², Makoto Nagaoka³, Hernan Valdez⁴, Michael Vincent¹ and James D. Clark¹, ¹Pfizer Inc, Cambridge, MA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Tokyo, Japan, ⁴Pfizer Inc, New York, NY
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Rates of herpes zoster (HZ) were higher than observed with…
Abstract Number: 2851 • 2015 ACR/ARHP Annual Meeting
Anti-TNF Therapy Is Associated with an Increase in Serious Infections in Patients with Spondyloarthritis (SpA), Especially during the First 12 Monts of Treatment: Results from the GISEA Registry
Fabiola Atzeni¹, Marco Sebastiani², Valentina Panetta³, Fausto Salaffi⁴, Antonio Marchesoni⁵, Roberta Ramonda⁶, Florenzo Iannone⁷, Roberto Gorla⁸, Elisa Gremese⁹, Marcello Govoni¹⁰, Pier Carlo Sarzi-Puttini¹¹, Gianfranco Ferraccioli¹², Giovanni Lapadula¹³ and on behalf of GISEA group, ¹Rheumatology Unit, L. Sacco University Hospital of Milan, Milan, Italy, ²SC Reumatologia, Dipartimento di Medicine, Medicina d’Urgenza e Specialità Mediche, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy, ³L'altrastatistica -Consultancy & Training- Biostatistics office., Rome, Italy, ⁴Rheumatology Department, Polytechnic University of Marche, C. Urbani Hospital, Jesi,, Ancona, Italy, ⁵Day Hospital of Rheumatology, G. Pini Orthopedic Institute, Chair of Rheumatology of Milan, Milan, Italy, ⁶Cattedra, Voc Rheumatology, University of Padua, Padova, Italy, ⁷Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ⁸Rheumatology and Immunology Unit, Spedali Civili di Brescia, Brescia, Italy, ⁹Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ¹⁰Department of Medical Sciences, UOC of Rheumatology, Azienda Ospedaliero-Universitaria S. Anna-Ferrara, University of Ferrara, Cona Ferrara, Italy, ¹¹Rheumatology Unit, University Hospital L Sacco, Milan, Italy, ¹²Rheumatology and Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy, ¹³Bari University, Rheumatology, Bari, Italy
Background/Purpose: Infection is by far the most common and most important adverse effect of TNF inhibitors (TNFI) in the treatment of rheumatoid arthritis (RA) and…
Abstract Number: 674 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics of Japanese Patients with Reactive Arthritis Induced By Intravesical BCG Therapy for Bladder Cancer: A 19 Years Two-Center Retrospective Study
Hirofumi Nishikawa¹, Yoshinori Taniguchi¹, Takashi Karashima², Tetsushi Aita³, Susumu Nishiyama³, Yasuhiko Yoshinaga³, Yoshitaka Kumon⁴, Yoshiko Shimamura¹, Kosuke Inoue¹, Taro Horino¹, Taro Shuin² and Yoshio Terada¹, ¹Kochi University, Nankoku, Japan, ²Urology, Kochi University, Nankoku, Japan, ³Kurashiki Medical Center, Kurashiki, Japan, ⁴Chikamori Hospital, Kochi, Japan
Background/Purpose: Intravesical instillation of BCG is used as an effective immunotherapy of bladder cancer. However it may have, as adverse event, a reactive arthritis (ReA)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].